Wockhardt Limited
WOCKPHARMA
Clasificación en acciones
#4515
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Precio por acción
$21.04
Última sincronización: 2026-10-19
Capitalización bursátil
$3.42B
Cambio (1 día)
-2.39%
Cambio (1 año)
34.90%
País
IN
Comercio Wockhardt Limited (WOCKPHARMA)
Categoría
Healthcare
Ganancias de Wockhardt Limited (WOCKPHARMA)
Ganancias en Jun 2026 TTM: $51.10M
Secondo gli ultimi rapporti finanziari di Wockhardt Limited, gli utili attuali della società sono $51.10M. Nel 2024, la società ha registrato un utile di $-50.37M, un aumento con respecto a agli utili del 2023, che erano di $-75.93M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Wockhardt Limited desde 2004 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $51.10M | -2,831.29% |
| 2025 | $-1.87M | -96.29% |
| 2024 | $-50.37M | -33.66% |
| 2023 | $-75.93M | 40.24% |
| 2022 | $-54.14M | -30.22% |
| 2021 | $-77.59M | 70.90% |
| 2020 | $-45.40M | -29.40% |
| 2019 | $-64.31M | -34.69% |
| 2018 | $-98.47M | 158.38% |
| 2017 | $-38.11M | -187.03% |
| 2016 | $43.79M | -52.51% |
| 2015 | $92.20M | -37.95% |
| 2014 | $148.59M | -56.05% |
| 2013 | $338.11M | 197.28% |
| 2012 | $113.73M | 385.74% |
| 2011 | $23.41M | -110.67% |
| 2010 | $-219.46M | 324.20% |
| 2008 | $-51.73M | -142.94% |
| 2007 | $120.48M | 81.57% |
| 2006 | $66.36M | 1.54% |
| 2005 | $65.35M | 13.32% |
| 2004 | $57.67M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $1.35B | 2,541.82% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -48.39% |
US
|
